ACTIVITY OVERVIEW | This Webcast contains video and downloadable slides from the symposium Optimizing Sequential Endocrine Therapy for Metastatic Breast Cancer, a prIME Oncology educational activity that was held at the 2011 Oncology Annual Meeting in Chicago, Illinois, United States. |
FACULTY | Chair
Harold Burstein, MD, PhD
Dana-Farber Cancer Institute
Boston, Massachusetts,
United States
Faculty
Fatima Cardoso, MD
Champalimaud Cancer Center
Lisbon, Portugal
Matthew Ellis, MD, PhD, FRCP
Washington University
School of Medicine
St Louis, Missouri, United States
Antonio Llombart Cussac, MD, PhD
Hospital Universitario
Arnau de Vilanova
Valencia, Spain
Hope Rugo, MD
University of California,
San Francisco
San Francisco, California,
United States |
TARGET AUDIENCE | This educational activity is specifically designed for non-US medical oncologists, surgical and radiation oncologists, and other healthcare providers interested and/or involved in the treatment of patients with endocrine-responsive breast cancer. |
|
|
 |
|
Expert Discussion
|
 |
|
Clinical Case
|
 |
|
Downloadable Slides
|
|
 |
TOPICS | Clinical scenario #1
Making the best choice for disease progression for endocrine-responsive metastatic breast cancer
Hope Rugo, MD
Clinical scenario #2
Managing recurrent breast cancer after adjuvant endocrine therapy
Antonio Llombart Cussac, MD, PhD
Clinical scenario #3
Treatment of endocrine-responsive advanced male breast cancer
Fatima Cardoso, MD
Can we overcome endocrine therapy resistance in breast cancer?
Matthew Ellis, MD, PhD, FRCP |
LEARNING OBJECTIVES | After successful completion of this educational activity, participants should be able to:
- Discuss the sequencing of hormonal therapies beyond the first-line setting for patients with hormone receptor-positive metastatic breast cancer
- Evaluate treatment options for male patients with endocrine responsive breast cancer, particularly after progression on selective estrogen receptor modulator therapy
- Examine current data regarding the mechanisms of endocrine resistance and the rationale for therapeutic strategies to overcome resistance
- Assess novel therapeutic approaches for refractory hormone receptor–positive metastatic breast cancer, including new endocrine therapies and combinatorial strategies with targeted agents
|
|
|
|
SUPPORT | This educational activity is supported by AstraZeneca.
|
|
